Veloxis Pharmaceuticals garners $60 mln debt funding
Denmark and Cary, North Carolina-based Veloxis Pharmaceuticals, which is focused on treating transplant patients, has secured $60 million in debt funding from Athyrium Capital Management. The capital will be used to refinance outstanding debt, accelerate the growth of Envarsus XR in the U.S. and for working capital.
14 February 2018•3 mins read
